Syneos Health has entered a multi-year strategic agreement with Microsoft. Using Microsoft Azure services, Syneos Health has developed an advanced analytics platform designed to enable agile deployment of machine learning (ML) supporting the analysis, design and execution of clinical trials and commercial programs worldwide.
 
The agreement includes collaboration with Microsoft Research and leverages developments from OpenAI. Syneos Health will deliver technology and data solutions with Microsoft that aim to accelerate clinical development and elevate commercial performance for biopharma customers.
 
Based on this AI-enabled platform, Syneos Health is able to process and analyze data to help fast-track timelines, optimize resource allocation and create clinical trial efficiencies. These capabilities aim to allow for superior site selection and reduced enrollment timelines to advance new treatments.
 
“Microsoft is the ideal technology partner for Syneos Health,” said Michelle Keefe, CEO, Syneos Health. “Their clear industry leadership in AI and their pragmatic approach to improving healthcare outcomes for patients, science and industry is completely aligned with our value proposition. We look forward to a strong relationship for years to come – one that drives innovative solutions to accelerate our customers’ success.”
 
“We are pleased to work with Syneos Health to bring our expertise in AI together with their solutions to help make a meaningful difference in the lives of patients,” said Patty Obermaier, Vice President, U.S. Health and Life Sciences, Microsoft. “Syneos Health’s integration of Azure Synapse Analytics, Azure Data Factory, Azure SQL Database, and other Azure services, allows them to develop a platform that empowers biopharma customers to deliver therapies to patients faster.”